Modern-day medicine has been revolutionized and personalized to cater to more specific disease characteristics. A prime example of this innovation is monoclonal antibodies (“mAbs”) and nanosized antibodies (NanoAbs), therapeutic options that address diseases in ways other therapies cannot. Several companies are penetrating the market and a compelling comparison can be made between two – one supporting mAbs and the other NanoAbs. Both companies share similar objectives and stages of development.
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is focused on the development of NanoAbs derived from alpacas. Alpaca-derived antibodies, also called VHH-antibodies, exhibit the potential for superior biobetter therapies that could be used for a wide range of diseases. BiondVax’s current pipeline is targeting COVID-19, psoriasis, asthma, and other diseases with large unmet medical needs – with collaboration from the prestigious Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”), both in Germany.
Apogee Therapeutics (NASDAQ: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications, is focused on the development of conventional mAbs therapeutics (https://ibn.fm/z8e1F). The company’s technology approach has been shown to create antibodies with significantly extended half-life and other optimized properties. The primary enhancement that Apogee hopes to achieve through its mAb development is a slightly longer duration of benefit and slightly fewer drug administrations.
Despite the benefits that conventional mAbs offer, BiondVax’s NanoAbs may offer superior benefits that Apogee’s formulations cannot, such as:
The potential benefits of BiondVax’s NanoAbs have been showcased in the company’s own pre-clinical studies, and the company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing.
Apogee and BiondVax are targeting the immune system’s IL-17 cytokine as they develop their drugs; IL-17 is involved in several diseases with BiondVax initially targeting IL-17 towards a psoriasis treatment.
The global psoriasis treatment market was valued at $26.13 billion in 2022 and is anticipated to reach $57.84 billion by 2031, growing at a CAGR of 9.23% (https://ibn.fm/EfBfN). The market is expected to grow at this rate due to the increased awareness of the affliction and the advancement in therapies associated with it. BiondVax’s VHH antibodies propose a different approach to treatment, which does not necessarily compete head-to-head with treatment options, but provides a unique alternative approach.
Apogee only recently went public a few weeks ago at $500 million pre-money, raising $300 million in an upsized deal, and now the company has a $1 billion market cap. BiondVax’s NanoAb advantages over Apogee’s mAbs offer an attractive prospect to investors who are looking to get in early on the “bio better” antibody movement. With huge potential and a market cap that’s currently miniscule in comparison, only about $5 million and trading under a $1.50 per share, its little wonder that Aegis Capital reiterated its buy rating with a $7 price target (https://ibn.fm/wFWBO).
For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
immunotherapy against cancer. In many of these cases, the inflammation recurs, and the treatment impacts…
According to a survey conducted by Gallup Center and West Health, most Americans have no…
A study conducted recently in Ohio has found that wastewater can be a vital provider…
UC San Francisco-based scientists have developed a new immunotherapy that was successful in wiping out…
Immunotherapy has transformed cancer treatment, but the approach still faces challenges like lengthy preparation time…
The palpable euphoria surrounding the election of Democratic healthcare professionals to key positions in the…